BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed MIRM catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:aa2c10d092ddd73bece8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:MIRM P2 readout (est.): VANTAGE
DESCRIPTION:A Study to Evaluate Efficacy and Safety of an Investigational D
 rug Named Volixibat in Patients With Itching Caused by Primary Biliary Cho
 langitis\nNCT05050136 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Mirum Ph
 armaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Ticker MIRM (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT
 05050136\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05050136
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e6ec1ad92bd16007e09a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260925
DTEND;VALUE=DATE:20260926
SUMMARY:MIRM APPROVAL: ATEBRIOZ
DESCRIPTION:Approved 2026-09-25: ATEBRIOZ (NDA221198 ORIG1)\nConfidence: co
 nfirmed\nTicker MIRM (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221198\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=221198
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
